AZD9977

DRUG6 trials

Sponsors

AstraZeneca

Conditions

Chronic Kidney DiseaseHealthy VolunteersHeart FailureHeart Failure With Preserved Ejection Fraction (HFpEF)Renal Impairment

Phase 1

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

CompletedNCT03435276

AstraZenecaHealthy Volunteers

Start: 2018-02-27End: 2018-06-13Updated: 2018-06-21

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

TerminatedNCT03682497

AstraZenecaHeart Failure

Start: 2018-11-01End: 2020-03-31Updated: 2020-05-01

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

CompletedNCT03801967

AstraZenecaHeart Failure

Start: 2019-01-24End: 2019-05-02Updated: 2019-05-10

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

CompletedNCT03843060

AstraZenecaHeart Failure With Preserved Ejection Fraction (HFpEF)

Start: 2019-02-22End: 2019-04-01Updated: 2019-04-22

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

CompletedNCT04469907

AstraZenecaRenal Impairment

Start: 2020-06-22End: 2021-10-28Updated: 2022-03-11

Phase 2

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

CompletedNCT04595370

AstraZenecaChronic Kidney Disease, Heart Failure

Start: 2021-01-26End: 2023-09-22Updated: 2024-11-19

Related Papers

Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.

2025-09-18

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure2025-05-193 citations

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology2025-02-172 citations

P5713Clinical pharmacology of AZD9977, a novel, selective mineralocorticoid receptor (MR) modulator without K+-sparing properties

European Heart Journal2019-10-01